Welcome to C4 Therapeutics

At C4 Therapeutics we are developing novel drugs based on the DEGRONIMID™ paradigm. These drugs are a new class of small molecules that direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit.  This paradigm shift in drug development will potentially provide new opportunities to target traditionally difficult diseases and resistance mechanisms.

Latest News

C4 Therapeutics Appoints Andrea Armstrong as CAO

blue circlesCambridge, MA. – September 22, 2016 – C4 Therapeutics (C4T) today announced that Andrea Armstrong has been promoted to Chief Administrative Officer. She joined C4T as a human resources consultant in January, 2016 and transitioned to full-time as the Senior Vice President of Human Resources in June, 2016. Ms. Armstrong has led the human resources function with a focus on talent acquisition efforts and will now also assume responsibility for facilities and laboratory operations, environmental health and safety, IT and office management, and internal communications.

“Andrea has been integral to the growth of C4T to this point,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “In addition to Andrea’s talents in human resources, her extensive organizational development and operational experience will bring much to our next phase of growth. I look forward to working with her in this expanded role.” read more...

Names C4 Therapeutics as one of its “Fierce 15” Biotech Companies of 2016

blue circlesCambridge, MA. – September 19, 2016C4 Therapeutics (C4T) today announced that it has been named by FierceBiotech as one of 2016’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

“We are humbled to be named a 2016 Fierce 15 company,” said Andrew Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics. “Since launching the company in January this year, the C4T team has rapidly built a world class science organization, made tremendous headway on internal projects, and moved forward with our partner Roche.  The Fierce15 award is a testament to this momentum, and also to the potential of our approach to targeted protein degradation for developing transformative new therapeutics.” read more...

C4 Therapeutics Appoints Andrew Phillips, Ph.D. as President and CSO

blue circlesCambridge, MA. – September 14, 2016 – C4 Therapeutics (C4T) today announced that Andrew Phillips, Ph.D. has been promoted to President and Chief Scientific Officer, reporting directly to Executive Chairman Marc Cohen. The Company also announced Jason Fisherman, M.D. has resigned as President/CEO and as a member of the Board of Directors to pursue other professional opportunities. Since joining C4T as Chief Scientific Officer in January 2016, Dr. Phillips has been leading the development of Targeted Protein Degradation (TPD) therapeutics based on the Company’s groundbreaking Degronimid™ platform.  read more...

What We Do

To discover and develop drugs targeting protein degradation to meaningfully advance the treatment of cancer and other life-impairing diseases.

In June 2015, Jay Bradner, MD and co-workers at the Dana-Farber Cancer Institute, showed that derivatives of thalidomide could be used to target specific proteins for degradation. This ground breaking research, which began in 2011, is now being advanced toward clinical impact by C4 Therapeutics, which was founded in late 2015 by Dr Bradner, along with Ken Anderson, MD, Nathanael Gray PHD, and Marc Cohen.
At C4 Therapeutics, we are combining world-class expertise in medicinal chemistry, protein biochemistry, biophysics and structural biology with pharmacology and disease biology. Our approach - which is centred on the Degronimid™ platform - prizes innovative and collaborative science, both internally and externally.


Contact Us

PhmailiconTelephone:   +1  617 588 6114

Email:   C4 Therapeutics